Close Menu

Pfizer has acquired the worldwide rights to sell insulin and insulin analogs being developed by Indian biotech company Biocon, in an attempt to work its way into the generic biotech drug market, says the New York Times' Andrew Pollack in the Prescriptions blog. Pfizer will pay Biocon $200 million initially, and then another $150 million, while Biocon manufactures the insulin. Other pharma companies are also getting into the biologic market, Pollack says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.